The Human Tissue Authority (HTA) has today published its strategy for 2024-2027, setting out its vision and priorities for regulating the use of human tissue over the next three years.
Key Points:
- The strategy focuses on maintaining public trust and confidence in the safe handling of human tissue, cells and organs.
- Four strategic priorities are outlined: approach to regulation, trust and confidence, use of information, and efficiency and effectiveness.
- The HTA aims to be a more outcome-focused and proportionate regulator, using data and intelligence to target resources.
- There is an emphasis on collaboration with stakeholders and supporting innovation in the life sciences sector.
- The strategy reaffirms core principles of consent, dignity, quality, honesty and openness.
Lynne Berry CBE, Chair of the HTA, said:
"Over the next three years, we anticipate changes and opportunities for growth across the sectors we regulate. Our strategy positions us to support innovation through a proportionate and collaborative approach to regulation."
Dr Colin Sullivan, Chief Executive of the HTA, commented:
"This new strategy reflects our journey as a flexible and responsive regulator. We aim to maintain trust and confidence while supporting licensed establishments to deliver safe care with dignity and respect."
Background:
The HTA is the independent regulator for organisations that remove, store and use human tissue for research, medical treatment, post-mortem examination, education and training, and public display. It also approves organ and bone marrow donations from living people.
The full strategy document is available here: HTA strategy 2024 to 2027 | Human Tissue Authority